Work Now To Build The Alzheimer's Commercial Landscape, McClellan Advises
Duke Margolis Center for Health Policy director Mark McClellan recommended CMS and drug manufacturers coordinate to build a clearer commercial path for Alzheimer's treatments.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Lynparza poised for expansion in prostate cancer; zuranolone faces challenges in depression; Novartis transfers products and cuts jobs in India; US call to build Alzheimer’s infrastructure; and Indian legal row over COVID spray product.
The company's comments to CMS on the proposed NCD for amyloid-targeting therapies for Alzheimer's disease says the differences between Alzheimer's and other areas could represent a legal issue.
Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align
Proposed decision withholds Medicare coverage from current and future amyloid-directed monoclonal antibody drugs for Alzheimer’s disease unless patients are enrolled in a randomized clinical trial.